Dr. Fonzo reports having done consulting work for Synapse Bio AI and Alto Neuroscience and owning equity in Alto Neuroscience. Dr. Nemeroff reports serving as a consultant or on the Scientific Advisory Boards for ANeuroTech (division Anima BV), Janssen Research and Development, BioXcel Therapeutics, Engrail Therapeutics, Clexio Biosciences LTD, EmbarkNeuro, Galen Mental Health LLC, Goodcap Pharmaceuticals, ITI Inc, LUCY Scientific Discovery, Relmada Therapeutics, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Skyland Trails, Denovo Biopharma, and the Brain & Behavior Research Foundation; owning the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551,996B2); and owning stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Relmada Therapeutics, Signant Health, Galen Mental Health LLC, and Senseye Inc. Disclosures of Editors’ financial relationships appear in the April 2024 issue of the Journal.